Program
Insulin Aspart
Also written as “insulin aspart”, “biphasic insulin aspart” and “Faster-acting insulin aspart”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Diabetes, Gestational, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 1280 open or running | phase 4since Nov 4, 2004 | Jul 17, 2003 | none ahead |
| Amphastar Pharmaceuticals | 20 open or running | phase 3since Sep 12, 2022 | Sep 12, 2022 | none ahead |
| Geropharm | 20 open or running | phase 3since Sep 3, 2019 | Sep 3, 2019 | none ahead |
| Profil Institut für Stoffwechselforschung | 20 open or running | phase 1since Aug 8, 2007 | Aug 8, 2007 | none ahead |
| cequr-corporation | 10 open or running | no phasesince Mar 24, 2015 | Mar 24, 2015 | none ahead |
| defymed | 11 open or running | no phasesince Dec 3, 2021 | Dec 3, 2021 | Dec 2026NCT05221359 |
| Sunshine Lake Pharma | 10 open or running | phase 3since Mar 6, 2023 | Mar 6, 2023 | none ahead |
| The United Laboratories International | 10 open or running | no phasesince May 6, 2026 | May 6, 2026 | none ahead |
| Tonghua Dongbao Pharmaceutical | 10 open or running | phase 3since Jun 5, 2015 | Jun 5, 2015 | none ahead |
Also a collaborator on its studies: mylan-gmbh and Sanofi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Nov 25, 2011.
- Jul 4, 2016Phase 3 study in Diabetes MellitusNovo Nordisk · NCT02825251 · 472 enrolled · United States, Belgium, Canada and more
- Jul 22, 2016Phase 1 study in HealthyNovo Nordisk · NCT02844790 · 24 enrolled · China
- Sep 15, 2016Phase 3 study in Diabetes MellitusNovo Nordisk · NCT02906917 · 532 enrolled · United States, Algeria, Czechia and more
- Oct 13, 2016Phase 1 study in Diabetes MellitusNovo Nordisk · NCT02933853 · 61 enrolled · Austria
- Jun 29, 2017Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03215498 · 58 enrolled · Germany
- Jan 5, 2018Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03407599 · 46 enrolled · Germany
- Jan 23, 2019Phase 2 study in Diabetes Mellitus, Type 1Novo Nordisk · NCT03816761 · 24 enrolled · United States
- Sep 3, 2019Geropharm's first study: phase 3 study in Diabetes MellitusNew to GeropharmGeropharm · NCT04079413 · 264 enrolled · Russian Federation
- Nov 29, 2019No phase study in Clamp StudyGeropharm · NCT04184466 · 26 enrolled · Russian Federation
- Dec 3, 2021defymed's first study: no phase study in Diabetes Mellitus, Type 1New to defymeddefymed · NCT05221359 · 8 planned · France
- Sep 12, 2022Amphastar Pharmaceuticals's first study: phase 3 study in PharmacokineticsNew to Amphastar PharmaceuticalsAmphastar Pharmaceuticals · NCT05539872 · 69 enrolled · United States
- Mar 6, 2023Sunshine Lake Pharma's first study: phase 3 study in Diabetes MellitusNew to Sunshine Lake PharmaSunshine Lake Pharma · NCT05802862 · 414 enrolled · China
- Apr 24, 2026Phase 3 study in PharmacokineticsAmphastar Pharmaceuticals · NCT07560150 · 62 enrolled · United States
- May 6, 2026The United Laboratories International's first study: no phase study in Pharmacokinetics and PharmacodynamicsNew to The United Laboratories InternationalThe United Laboratories International · NCT07600944 · 44 enrolled · China
Ahead
- Dec 2026Primary completion: no phase study in Diabetes Mellitus, Type 1defymed · NCT05221359
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The newest 60 of 139 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07600944Pharmacokinetics and Pharmacodynamics · China | – | Completed | The United Laboratories International | Jun 13, 2026 | 44 |
| NCT07560150Pharmacokinetics · United States | 3 | Completed | Amphastar Pharmaceuticals | Jun 22, 2026 | 62 |
| NCT05802862Diabetes Mellitus · China | 3 | Completed | Sunshine Lake Pharma | Aug 16, 2024 | 414 |
| NCT05539872Pharmacokinetics · United States | 3 | Completed | Amphastar Pharmaceuticals | Jan 29, 2023 | 69 |
| NCT05221359Diabetes Mellitus, Type 1 · France | – | Recruiting | defymed | Dec 2026 | 8 |
| NCT04184466Clamp Study · Russian Federation | – | Completed | Geropharm | Dec 19, 2018 | 26 |
| NCT04079413Diabetes Mellitus · Russian Federation | 3 | Completed | Geropharm | Jan 21, 2020 | 264 |
| NCT03816761Diabetes Mellitus, Type 1 · United States | 2 | Completed | Novo Nordisk | May 31, 2019 | 24 |
| NCT03407599Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 5, 2018 | 46 |
| NCT03215498Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Nov 20, 2017 | 58 |
| NCT02933853Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Dec 21, 2017 | 61 |
| NCT02906917Diabetes Mellitus · United States, Algeria, Czechia and more | 3 | Completed | Novo Nordisk | Aug 31, 2017 | 532 |
| NCT02844790Healthy · China | 1 | Completed | Novo Nordisk | Sep 26, 2016 | 24 |
| NCT02825251Diabetes Mellitus · United States, Belgium, Canada and more | 3 | Completed | Novo Nordisk | Jun 20, 2017 | 472 |
| NCT02762578Diabetes Mellitus · China | 3 | Completed | Novo Nordisk | May 19, 2017 | 543 |
| NCT02670915Diabetes Mellitus · United States, Bulgaria, Czechia and more | 3 | Completed | Novo Nordisk | Feb 5, 2018 | 834 |
| NCT02648217Diabetes Mellitus · Algeria, India, Lebanon and more | 3 | Completed | Novo Nordisk | Sep 4, 2016 | 263 |
| NCT02594033Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jan 28, 2016 | 46 |
| NCT02568280Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Apr 25, 2016 | 42 |
| NCT02500706Diabetes Mellitus · United States, Austria, Bulgaria and more | 3 | Completed | Novo Nordisk | Jul 17, 2017 | 1,108 |
| NCT02491528Diabetes Mellitus · China | 3 | Completed | Tonghua Dongbao Pharmaceutical | Aug 12, 2016 | 563 |
| NCT02419859Diabetes Mellitus, Type 2 · Austria | – | Completed | cequr-corporation | Nov 2015 | 20 |
| NCT02131246Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Jul 2014 | 33 |
| NCT02089451Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jun 6, 2014 | 21 |
| NCT02035371Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 24, 2014 | 41 |
| NCT02033239Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jun 2014 | 46 |
| NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico | 3 | Completed | Novo Nordisk | Jan 11, 2016 | 501 |
| NCT02003677Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Aug 14, 2014 | 67 |
| NCT01999322Diabetes Mellitus · United States, Germany | 3 | Completed | Novo Nordisk | May 14, 2014 | 37 |
| NCT01992588Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Mar 2014 | 48 |
| NCT01934712Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Jan 28, 2014 | 50 |
| NCT01924637Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Nov 2013 | 36 |
| NCT01892020Diabetes Mellitus · China | 4 | Completed | Novo Nordisk | May 2014 | 161 |
| NCT01868568Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Aug 2008 | 55 |
| NCT01868555Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Feb 2008 | 32 |
| NCT01865331Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Mar 2007 | 32 |
| NCT01865305Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Feb 2007 | 59 |
| NCT01835431Diabetes Mellitus · United States, Belgium, Brazil and more | 3 | Completed | Novo Nordisk | Nov 7, 2014 | 362 |
| NCT01814137Diabetes Mellitus · United States, Algeria, Germany and more | 3 | Completed | Novo Nordisk | Mar 2014 | 40 |
| NCT01773798Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Aug 2013 | 33 |
| NCT01713530Diabetes Mellitus · United States, Algeria, Austria and more | 3 | Completed | Novo Nordisk | Jan 9, 2014 | 274 |
| NCT01707134Diabetes Mellitus · Austria, Denmark, Finland and more | 3 | Completed | Novo Nordisk | May 2000 | 753 |
| NCT01704378Diabetes Mellitus · Finland, Norway, Sweden and more | 4 | Completed | Novo Nordisk | Mar 14, 2003 | 89 |
| NCT01698697Diabetes Mellitus · South Africa | 1 | Completed | Novo Nordisk | Oct 18, 2002 | 24 |
| NCT01682902Diabetes Mellitus · United States | 1 | Completed | Novo Nordisk | Mar 2013 | 43 |
| NCT01650129Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Oct 18, 2001 | 83 |
| NCT01620437Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Dec 30, 2003 | 30 |
| NCT01620333Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Apr 2000 | 24 |
| NCT01618188Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Sep 7, 2012 | 52 |
| NCT01538511Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Mar 13, 2007 | 59 |
| NCT01536028Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 2006 | 32 |
| NCT01530048Diabetes Mellitus · Denmark | 1 | Completed | Novo Nordisk | May 2006 | 34 |
| NCT01527656Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Feb 2004 | 40 |
| NCT01527643Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Dec 17, 2003 | 30 |
| NCT01527630Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Jan 8, 2003 | 30 |
| NCT01527565Diabetes Mellitus · South Africa | 1 | Completed | Novo Nordisk | Feb 26, 2003 | 30 |
| NCT01527552Diabetes Mellitus · South Africa | 1 | Completed | Novo Nordisk | Dec 18, 2002 | 30 |
| NCT01526980Diabetes Mellitus · United Kingdom | 2 | Completed | Novo Nordisk | Nov 2002 | 31 |
| NCT01526941Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 2001 | 27 |
| NCT01649570Diabetes Mellitus · Japan | 4 | Completed | Novo Nordisk | Aug 2003 | 123 |
How it is read
Names in the registry
- “insulin aspart”, 60 entries
- “biphasic insulin aspart”, 27 entries
- “Faster-acting insulin aspart”, 24 entries
- “biphasic insulin aspart 50”, 13 entries
- “biphasic insulin aspart 70”, 12 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 57 studies
- Diabetes Mellitus, Type 1, 54 studies
- Diabetes Mellitus, 28 studies
- Diabetes, Gestational, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.